MedTrace Logo

Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan

NCT03706222 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2019-03-13

No results posted yet for this study

Summary

Co-morbid diseases often present in a substantial proportion of patients with chronic hepatitis C (CHC) and require drugs to treat and control. Grazoprevir/elbavir is metabolized by cytochrome P-450 enzyme of liver. Drug-drug interactions (DDIs) are important issue before commencing direct acting antiviral agents (DAA) treatment for CHC patients. Few studies from Western countries reported that the percentages of DDIs of grazoprevir/elbasvir are limited.In Asia, real-world analysis of DDIs of grazoprevir/elbasvir is lacking and needs to be clarified.

Conditions

  • Drug Interaction Potentiation

Interventions

DRUG

elbasvir/grazoprevir

Comedications during elbasvir/grazoprevir will be recorded and analyzed for potential drug-drug interaction.

Sponsors & Collaborators

Principal Investigators

  • Pin-Nan Cheng, M.D. · National Cheng-Kung University Hospital

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-22
Primary Completion
2019-02-25
Completion
2019-02-25
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03706222 on ClinicalTrials.gov